Apexigen, Inc. (APGN)

NASDAQ: APGN · IEX Real-Time Price · USD
7.23
-0.39 (-5.12%)
Aug 16, 2022 3:22 PM EDT - Market open
-5.12%
Market Cap 155.05M
Revenue (ttm) n/a
Net Income (ttm) -37.79M
Shares Out 21.44M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 102,071
Open 7.49
Previous Close 7.62
Day's Range 6.93 - 7.71
52-Week Range 5.11 - 31.35
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About APGN

Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinica... [Read more...]

Industry Biotechnology
Founded 2010
Employees 27
Stock Exchange NASDAQ
Ticker Symbol APGN
Full Company Profile

Financial Performance

Financial Statements

News

Vintage Wine Estates announces plans to go public via SPAC

VintageWineEstatesgoespublic Vintage Wine Estates (“VWE”) president Terry Wheatley, who is poised to become the first female president of a multi-hundred million dollar wine producer in American history...